Telmisartan (Micardis)

FDA Approved

Angiotensin II Receptor Blocker | Cardiac Protection On Cycle

Weight: 514.62 Da

Half-life: ~24 hours

5 studies

2017 latest

2 recent

FDA Approved

Dose 20-80 mg/day

Frequency Once daily

Cycle Ongoing (duration of AAS cycle or chronic use)

Storage Room temperature (59-86F). Protect from moisture.

Accumulation Plotter

Community Research

Join others researching Telmisartan — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings

Discussion Questions & experiences

Submit Your Findings Contribute your research data

Telmisartan is an angiotensin II receptor blocker (ARB) originally developed for the treatment of hypertension and cardiovascular risk reduction. FDA-approved since 1998 and marketed as Micardis, it has become the preferred ARB among performance-enhancing drug users and anabolic steroid communities due to its long half-life, strong evidence for organ protection, and unique partial PPAR-gamma agonist activity. Unlike other ARBs, telmisartan activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) at clinically relevant doses, conferring metabolic benefits that extend beyond blood pressure reduction. Anabolic androgenic steroids (AAS) are well-documented to elevate blood pressure, promote left ventricular hypertrophy, accelerate atherosclerosis, and impair renal function -- making proactive cardiovascular protection an essential component of harm reduction. Telmisartan addresses these concerns with once-daily dosing, 24-hour blood pressure coverage, and a favorable side effect profile that does not impair exercise performance or recovery.

Mechanism of Action

Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling. This is particularly relevant for AAS users, where supraphysiological androgen levels stimulate the renin-angiotensin-aldosterone system (RAAS) and promote myocardial fibrosis and left ventricular hypertrophy. Telmisartan also has the longest half-life of any ARB (approximately 24 hours), providing consistent receptor blockade throughout the dosing interval. Its unique partial agonism of PPAR-gamma -- a nuclear receptor involved in glucose and lipid metabolism -- distinguishes it from other ARBs. PPAR-gamma activation enhances insulin sensitivity, improves adiponectin secretion, reduces visceral fat accumulation, and exerts anti-inflammatory effects. Additionally, telmisartan demonstrates nephroprotective properties by reducing intraglomerular pressure and proteinuria, and has been shown in the ONTARGET trial to provide cardiovascular protection comparable to the ACE inhibitor ramipril in high-risk patients.

01 Potent 24-hour blood pressure reduction with once-daily dosing

02 Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling

03 Nephroprotection through reduced intraglomerular pressure and proteinuria

04 Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism

05 No negative impact on exercise performance, VO2 max, or recovery

06 Reduction of pathological vascular remodeling and arterial stiffness

07 Longest half-life of all ARBs ensuring consistent 24-hour coverage

08 Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)

Molecular Data

Molecular Weight

514.62 Da

Type

Benzimidazole derivative (C33H30N4O2)

Peak 0.0 mcg

Trough 0.0 mcg

SS Peak 0.0 mcg

SS Trough 0.0 mcg

Research Indications

Cardiovascular Protection

Hypertension most effective

FDA-approved for treatment of essential hypertension as monotherapy or in combination with other antihypertensives. Provides consistent 24-hour blood pressure reduction. Particularly effective for AAS-induced hypertension where elevated blood pressure is driven by RAAS activation and increased erythropoiesis.

Cardiovascular Risk Reduction most effective

FDA-approved for reduction of cardiovascular morbidity in patients at high risk. The ONTARGET trial demonstrated non-inferiority to ramipril for the composite of cardiovascular death, MI, stroke, and hospitalization for heart failure in over 25,000 high-risk patients.

AAS-Induced Cardiac Remodeling effective

Angiotensin II receptor blockade counteracts the pro-hypertrophic and pro-fibrotic effects of supraphysiological androgen levels on the myocardium. Preclinical and observational data support the use of ARBs to attenuate left ventricular hypertrophy in steroid users. Widely recommended in harm reduction protocols.

Renal Protection

Nephroprotection effective

Reduces intraglomerular pressure and proteinuria by blocking angiotensin II-mediated efferent arteriolar constriction. Slows progression of chronic kidney disease, particularly in patients with diabetic nephropathy or hypertensive nephrosclerosis. Relevant for AAS users where elevated blood pressure and NSAID co-use may compromise renal function.

Metabolic Health

Insulin Sensitivity Improvement moderate

Telmisartan's partial PPAR-gamma agonism improves insulin sensitivity without the weight gain associated with full PPAR-gamma agonists like pioglitazone. May reduce the risk of new-onset diabetes in hypertensive patients. The metabolic benefit is particularly relevant for users of compounds that impair glucose tolerance (e.g., growth hormone, trenbolone).

Dosing Protocols

Telmisartan is administered exclusively via the oral route as a tablet. It reaches peak plasma concentration approximately 0.5-1 hour after administration, with absolute bioavailability of approximately 42-58% (dose-dependent). The drug is highly lipophilic, extensively protein-bound (>99.5%), and has a large volume of distribution (~500 L), contributing to its long duration of action. Telmisartan undergoes hepatic glucuronidation (not CYP450-dependent) and is eliminated primarily through biliary/fecal excretion, making it suitable for patients with mild to moderate renal impairment without dose adjustment.

Goal	Dose	Frequency	Route
AAS Cycle - Cardiac Protection	40-80 mg/day	Once daily	Oral
Mild Hypertension / Preventive Use	20-40 mg/day	Once daily	Oral
Standard Hypertension Treatment	40-80 mg/day	Once daily	Oral

Interactions

Testosterone

Highly recommended alongside testosterone and other AAS. Telmisartan directly counteracts AAS-induced RAAS activation, blood pressure elevation, and cardiac remodeling. No pharmacokinetic interactions. Considered a cornerstone of on-cycle cardiac protection in harm reduction protocols.

compatible

Tadalafil

Telmisartan and tadalafil have complementary blood pressure-lowering mechanisms -- ARB-mediated RAAS blockade and PDE5 inhibitor-mediated vasodilation, respectively. The combination provides enhanced BP control and may offer additive vascular and renal protective effects. Start tadalafil at a low dose (5 mg) when already on telmisartan and monitor for symptomatic hypotension.

synergistic

ACE Inhibitors

Combining an ARB with an ACE inhibitor (dual RAAS blockade) provides no additional cardiovascular benefit and significantly increases the risk of hyperkalemia, hypotension, and renal impairment. The ONTARGET trial demonstrated that telmisartan plus ramipril was associated with more adverse events without additional benefit compared to either agent alone. Use one or the other, not both.

avoid

NSAIDs

Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, etc.) can blunt the antihypertensive effect of telmisartan by inhibiting renal prostaglandin synthesis. Concurrent use also increases the risk of acute kidney injury, particularly in volume-depleted states. If NSAID use is necessary, monitor blood pressure and renal function closely. Consider acetaminophen as an alternative analgesic.

monitor

What to Expect

Day 1-3

Blood pressure begins to decrease within 3 hours of the first dose. Initial reductions are modest as steady-state has not yet been reached. Some users may experience mild dizziness or lightheadedness, particularly if starting at 80 mg or if already on the lower end of normal blood pressure.

Week 1-2

Blood pressure reductions become more consistent as the drug approaches steady-state plasma levels (achieved by approximately day 7 with once-daily dosing). Most users will notice meaningful reductions in systolic and diastolic readings on home monitoring.

Week 2-4

Full antihypertensive effect is typically achieved within 4 weeks. Blood pressure should be reassessed at this point to determine if dose adjustment is needed. RAAS blockade is fully established, providing ongoing cardioprotective and nephroprotective effects.

Month 1-3

Sustained blood pressure control. PPAR-gamma-mediated metabolic improvements may begin to manifest, including modest improvements in fasting glucose and insulin sensitivity. Proteinuria reduction, if present, becomes measurable.

Month 3+

Long-term organ protection is the primary benefit of continued use. Ongoing attenuation of cardiac remodeling and arterial stiffness. Metabolic benefits from PPAR-gamma agonism are fully established. Annual monitoring of renal function and electrolytes is recommended.

Side Effects & Safety

Common Side Effects

Dizziness or lightheadedness, particularly during the first few days or after dose increases
Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
Back pain and myalgia (uncommon but reported)
Fatigue

Stop Signs - Discontinue if:

Signs of angioedema: swelling of face, lips, tongue, or throat with difficulty breathing
Severe persistent dizziness, fainting, or symptomatic hypotension unresponsive to hydration
Signs of hyperkalemia: muscle weakness, irregular heartbeat, tingling or numbness
Significant decrease in urine output or signs of acute kidney injury
Unexplained jaundice or severe abdominal pain suggesting hepatic injury

Contraindications

Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
Bilateral renal artery stenosis
Known hypersensitivity to telmisartan or any excipients
Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)

Quality Checklist

Good Signs

Pharmaceutical-grade product from established manufacturer with valid NDC number
Proper labeling with dosage strength (20 mg, 40 mg, or 80 mg), lot number, and expiration date
Tablets are uniform in appearance with no chips, cracks, or discoloration
Prescribed by licensed physician with baseline blood pressure and metabolic workup
Generic telmisartan from FDA-approved ANDA (bioequivalent to branded Micardis)

Warning Signs

Sourced from unverified international online pharmacies without prescription
Compounded formulations without verification of potency or dissolution testing
Product stored in excessive heat or humidity (telmisartan is hygroscopic)

Bad Signs

Tablets that are crumbling, discolored, or have unusual odor
Product past its expiration date
No labeling or incorrect dosage strength labeling
Sourced from underground labs or non-pharmaceutical suppliers

References

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events (ONTARGET)

Yusuf, S., Teo, K.K., Pogue, J., et al.

The New England Journal of Medicine (2008)

Landmark trial of 25,620 high-risk patients demonstrating that telmisartan was non-inferior to ramipril for the composite of cardiovascular death, MI, stroke, and heart failure hospitalization. The combination of telmisartan and ramipril increased adverse events (hypotension, syncope, renal dysfunction, hyperkalemia) without additional cardiovascular benefit.
Telmisartan as a unique PPAR-gamma modulator: implications in metabolic syndrome and beyond

Benson, S.C., Pershadsingh, H.A., Ho, C.I., et al.

Hypertension (2004)

Demonstrated that telmisartan activates PPAR-gamma at concentrations achieved with standard clinical dosing, distinguishing it from other ARBs. This partial agonism was associated with improved glucose and lipid metabolism in preclinical models, suggesting metabolic benefits beyond blood pressure reduction.
Effects of telmisartan on insulin resistance and visceral fat in type 2 diabetic patients

Nagel, J.M., Tietz, A.B., Goke, B., et al.

Diabetes Research and Clinical Practice (2006)

Clinical study showing that telmisartan 80 mg/day for 6 months significantly reduced insulin resistance (HOMA-IR), visceral fat area, and HbA1c in type 2 diabetic patients compared to baseline, supporting the clinical relevance of its PPAR-gamma agonist activity.
Cardiovascular effects of anabolic steroids in weight-trained subjects

Baggish, A.L., Weiner, R.B., Kanayama, G., et al.

Journal of the American College of Cardiology (2017)

Study demonstrating that long-term AAS use is associated with impaired left ventricular systolic function, diastolic dysfunction, and premature coronary atherosclerosis in experienced strength athletes, establishing the cardiovascular risk basis for proactive cardioprotection in AAS users.
Telmisartan for prevention of cardiovascular outcomes and new-onset diabetes (TRANSCEND)

Yusuf, S., Teo, K., Anderson, C., et al.

The Lancet (2008)

Trial of 5,926 ACE inhibitor-intolerant high-risk patients showing telmisartan reduced the secondary composite of cardiovascular death, MI, and stroke. Also demonstrated a trend toward reduced new-onset diabetes, consistent with the drug's PPAR-gamma-mediated metabolic benefits.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.